Purple Biotech (PPBT) Income from Continuing Operations (2014 - 2026)
Purple Biotech (PPBT) reported Income from Continuing Operations of 2200000.0 for Q1 2026, up 67.05% year-over-year from 1317000.0 in Q1 2025, and up 67.05% on a QoQ basis from 1317000.0 in Q1 2025.
Purple Biotech (PPBT) has 2 years of Income from Continuing Operations data on file, last reported at 2200000.0 in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Purple Biotech | 3.58 Bn | 3.57 Bn | - | 2.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.20 Mn |
| Dec 31, 2025 | 23.15 Mn |
| Sep 30, 2025 | 1.24 Mn |
| Jun 30, 2025 | 1.18 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | 629,000.00 |
| Sep 30, 2024 | 1.49 Mn |
| Jun 30, 2024 | 3.31 Mn |
| Mar 31, 2024 | 4.35 Mn |
| Dec 31, 2023 | 6.28 Mn |
| Sep 30, 2023 | 5.02 Mn |
| Jun 30, 2023 | 4.86 Mn |
| Mar 31, 2023 | 4.79 Mn |
| Dec 31, 2022 | 6.01 Mn |
| Sep 30, 2022 | 4.82 Mn |
| Jun 30, 2022 | 3.45 Mn |
| Mar 31, 2022 | 7.23 Mn |
| Dec 31, 2021 | 4.61 Mn |
| Sep 30, 2021 | 2.95 Mn |
| Jun 30, 2021 | 3.44 Mn |
| Mar 31, 2021 | 6.39 Mn |
| Dec 31, 2020 | 8.06 Mn |
| Dec 31, 2019 | 3.44 Mn |
| Dec 31, 2018 | 3.19 Mn |
| Dec 31, 2017 | 5.81 Mn |
| Dec 31, 2016 | 7.05 Mn |
| Dec 31, 2015 | 4.38 Mn |
| Sep 30, 2015 | 548,000.00 |
| Dec 31, 2014 | 600,000.00 |
| Sep 30, 2014 | 982,000.00 |